The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals-Reference-Cited by-同舟云学术

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

Published:1999-10 Issue:14 Volume:13 Page:F95-F99
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:AIDS

Author:

van Heeswijk Rolf P.G.,Veldkamp Agnes I.,Hoetelmans Richard M.W.,Mulder Jan W.,Schreij Gerrit,Hsu Ann,Lange Joep M.A.,Beijnen Jos H.,Meenhorst Pieter L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference10 articles.

1. Active human immunodeficiency virus protease is required for viral infectivity.

2. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

3. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

4. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

5. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review;Infectious Diseases and Therapy;2024-04-12

2. Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet;AAPS PharmSciTech;2018-06-04

3. Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors;Current HIV Research;2012-03-01

4. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection;AIDS;2011-09-24

5. Identification of a Potential Pharmacological Sanctuary for HIV Type 1 in a Fraction of CD4+Primary Cells;AIDS Research and Human Retroviruses;2010-01